Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0B5PK
|
|||
| Drug Name |
TEN010
|
|||
| Indication | Advanced solid tumour [ICD-11: 2A00-2F9Z; ICD-9: 140-199] | Phase 1 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [2] | ||
| Company |
Tensha Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bromodomain-containing protein 4 (BRD4) | Target Info | Modulator | [3] |
| WikiPathways | Chemical Compounds to monitor Proteins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02308761) A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome. U.S. National Institutes of Health. | |||
| REF 2 | Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.Nat Rev Drug Discov. 2016 Aug;15(8):533-50. | |||
| REF 3 | Targeting bromodomains: epigenetic readers of lysine acetylation.Nat Rev Drug Discov.2014 May;13(5):337-56. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.